Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Aaron Ciechanover, who received the Nobel Prize in Chemistry in 2004, is joining a Quintiles advisory board.

Dr. Ciechanover, a research professor in medicine at Technion Israel Institute of Technology, will advise the world’s largest life sciences services firm as part of its

“We are extremely pleased that he has joined other distinguished experts on Quintiles’ Scientific Advisory Board, and we look forward to Dr. Ciechanover’s involvement in our efforts to bring more effective oncology drugs to patients in need,” said Sarah Bacus, Quintiles’ senior vice president and chief scientific officer for Translational R&D – Oncology.

Dr. Ciechanover shared the Nobel Prize for work in discovery of so-called ubiquitin-mediated protein degradation, which is being researched as possible anti-cancer tool. He shared the Nobel with Avram Hershko and Irwin Rose.

The Quintiles board is looking to advance oncology drug development with an emphasis on biomarkers and targeted therapies.

“Dr. Ciechanover’s work continues to provide translational research insight into novel mechanisms of action,” Bacus said. “His expertise will provide Quintiles with great insight into the next generation of anti-cancer drugs targeting the ubiquitin pathway.

In a statement, Dr. Ciechanover said he had been “impressed” by Quintiles’ “key opinion leaders and scientific direction in oncology clinical development.”

“I am pleased to join its advisory board to help advance promising anti-cancer therapies from research through development and on to patients in need,” he added.

The Quintiles board now has 11 members.

Get the latest news alerts: at Twitter.